Le Lézard
Classified in: Covid-19 virus
Subjects: NPT, REL, AVO

Exclusive: EWTN News Nightly Anchor Tracy Sabol's Interview With President Donald J. Trump Airs Tonight


WASHINGTON, Aug. 4, 2020 /PRNewswire/ -- EWTN News Nightly Anchor Tracy Sabol conducted an exclusive interview with President Donald J. Trump this morning live from the Roosevelt Room in the West Wing of the White House. The interview will air at 6 p.m. ET, Tuesday (tonight), Aug.4, with a re-air at 9:10 p.m. ET.

Said Sabol: "We covered the economic recovery, COVID-19, the opening of schools, and violence against churches ? so tune in!"

Clips and a transcript, embargoed until 6:15 p.m. EDT airing, will be made available via the contact listed above. Credit must be made to EWTN News Nightly.

ABOUT EWTN

EWTN Global Catholic Network, founded in 1980, is the largest Catholic media network in the world. EWTN's 11 global TV channels are broadcast in multiple languages 24 hours a day, seven days a week to over 350 million television households in more than 145 countries and territories. EWTN platforms also include radio services transmitted through SIRIUS/XM, Sky satellite radio, iHeart Radio, and over 500 domestic and international AM & FM radio affiliates; a worldwide shortwave radio service; several of the most visited Catholic web, digital and social media outlets in the world; EWTN News; as well as EWTN Publishing, its book publishing division.

SOURCE EWTN Global Catholic Network


These press releases may also interest you

at 01:20
Biophytis Announces Ratio Change Under its American Depositary Receipt ("ADR") Program
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 - Exclusive Report by 360iResearch
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
SETC-Assistance.org Helps Eligible Self-Employed Workers Receive Up to $32,220 in Tax Credits Through SETC Program
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - QDEL
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

More news about Covid-19 virus...


News published on and distributed by: